Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) has earned a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $41.25.
A number of analysts have recently issued reports on the company. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. TD Cowen started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Lifesci Capital started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price target on the stock.
Get Our Latest Analysis on Oruka Therapeutics
Oruka Therapeutics Trading Up 0.7 %
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Read More
- Five stocks we like better than Oruka Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- What Are Some of the Best Large-Cap Stocks to Buy?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Consumer Staples Stocks, Explained
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.